The Lancet: UPGx-PREPARE Study

The world's largest study to date on the application of pharmacogenetic information shows that adaptation of medication to DNA variants leads to 30% fewer side effects

The study published in the journal The Lancet is the first to show the success rates of managing the prescribing of drugs based on a person's genetic information.

From a genetic perspective, ‘one size fits all’ is a very much outdated view for prescribing medicines. Our genetic differences mean that patients can respond very differently to the same drug.

Personalising treatment is the next stage in providing better patient outcomes and the ‘right medicine, right dose, first time’ becomes the new standard in medicine.

The Lancet study* showed that patients whose medication is adjusted according to their DNA had 30% less serious side effects than patients who were prescribed a standard dose of medication. About 7,000 patients from seven European countries were examined in various medical specialities, mainly patients treated in the fields of oncology, cardiology, psychiatry and general medicine.

Mantara Health works closely with Frankfurt-based digital health-genomics company bio.logis led by human genetics specialist and founder Prof. Daniela Steinberger,  in order to develop the Mantara DNA PGx Test in the UK.